Pasithea Therapeutics (KTTA) Cash from Discontinued Operations (2022 - 2023)

Pasithea Therapeutics recorded quarterly Cash from Discontinued Operations of 16895.0 in Q4 2023, down 50.18% quarter-over-quarter from 11250.0 in Q3 2023, and up 97.8% year-over-year from 8541.24 in Q4 2022.

Pasithea Therapeutics' Cash from Discontinued Operations history runs 2 years deep, the most recent figure standing at 16895.0 for Q4 2023.

  • In Q4 2023, Cash from Discontinued Operations rose 97.8% year-over-year to 16895.0; the TTM figure through Dec 2023 stood at 611278.0 (up 65.98% YoY), while the FY2023 annual figure was 611278.0, up 65.98% from the prior year.
  • Cash from Discontinued Operations came in at 16895.0 for Q4 2023 at Pasithea Therapeutics, down from 11250.0 in the prior quarter.
  • In the past five years, Cash from Discontinued Operations ranged from a high of 10698.0 in Q2 2022 to a low of 769680.0 in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Discontinued Operations (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn -
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -
10 Pasithea Therapeutics 17.41 Mn 17.41 Mn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2023 -16,895.00
Dec 31, 2023 -16,895.00
Sep 30, 2023 -11,250.00
Sep 30, 2023 -11,250.00
Jun 30, 2023 -399,689.00
Jun 30, 2023 -399,689.00
Mar 31, 2023 -183,444.00
Mar 31, 2023 -183,444.00
Dec 31, 2022 -769,680.00
Dec 31, 2022 -769,680.00
Sep 30, 2022 -626,357.00
Sep 30, 2022 -626,357.00
Jun 30, 2022 10,698.00
Jun 30, 2022 10,698.00
Mar 31, 2022 -411,252.00
Mar 31, 2022 -411,252.00